Management of Moderate Mitral Regurgitation with Severe Left Atrial Dilation

Introduction to Management

The European Society of Cardiology recommends that patients with moderate primary mitral regurgitation and severe left atrial dilation (LA volume index ≥60 mL/m²) should be referred to a comprehensive heart valve center for surgical evaluation, as severe LA dilation represents an indication for early intervention when performed at centers with high repair rates (>95%) and low operative mortality (<1%) 1, 2

Severe left atrial dilation in the setting of moderate mitral regurgitation signals advanced cardiac remodeling and warrants escalation of care, with an increased risk of developing atrial fibrillation, which independently worsens prognosis 3, 4
The presence of severe LA enlargement may lead to underestimation of mitral regurgitation severity, as LA compliance may mask hemodynamic consequences 5

Comprehensive echocardiographic re-evaluation is mandatory to confirm mitral regurgitation severity using multiple parameters, assess left ventricular function, measure pulmonary artery systolic pressure, and evaluate for new-onset atrial fibrillation 3, 4, 6, 7
The American College of Cardiology recommends measuring pulmonary artery systolic pressure, as resting pulmonary hypertension >50 mm Hg is a Class IIa indication for surgery even with preserved left ventricular function 4, 7

Immediate referral to a heart valve center is indicated when LA volume index ≥60 mL/m² with left ventricular ejection fraction (LVEF) >60% and left ventricular end-systolic dimension (LVESD) <40 mm, provided the procedure can be performed at a center with >95% repair success and <1% mortality 1, 2
The American College of Cardiology suggests that serial imaging demonstrating progressive left ventricular enlargement or declining LVEF, new-onset atrial fibrillation, or resting pulmonary hypertension are indications for intervention 3, 4, 7

For patients awaiting evaluation or not yet meeting surgical thresholds, clinical evaluation every 6 months with echocardiography and monitoring for symptom development is recommended 9
The European Society of Cardiology recommends optimizing cardiovascular risk factors, including strict blood pressure control and consideration of biomarkers to guide timing of intervention 1, 2, 8